Pharmacodynamic biomarker-driven trial of MK-2206, an AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma (CRC).
Giovanna Speranza
No relevant relationships to disclose
Robert J. Kinders
No relevant relationships to disclose
Sonny Khin
No relevant relationships to disclose
Marcie K. Weil
No relevant relationships to disclose
Khanh Tu Do
No relevant relationships to disclose
Yvonne Horneffer
No relevant relationships to disclose
Lamin Juwara
No relevant relationships to disclose
Deborah Allen
No relevant relationships to disclose
P. Mickey Williams
No relevant relationships to disclose
Chih Jian Lih
No relevant relationships to disclose
Larry Rubinstein
No relevant relationships to disclose
Laurence A Doyle
No relevant relationships to disclose
James H. Doroshow
No relevant relationships to disclose
Shivaani Kummar
No relevant relationships to disclose